428 related articles for article (PubMed ID: 27557643)
1. Treatment of acquired drug resistance in multiple myeloma by combination therapy with XPO1 and topoisomerase II inhibitors.
Turner JG; Dawson JL; Grant S; Shain KH; Dalton WS; Dai Y; Meads M; Baz R; Kauffman M; Shacham S; Sullivan DM
J Hematol Oncol; 2016 Aug; 9(1):73. PubMed ID: 27557643
[TBL] [Abstract][Full Text] [Related]
2. Selinexor for the treatment of patients with relapsed or refractory multiple myeloma.
Babar A; Babar M; Zubair H; Shahid A; Rafique S; Bano M; Waleed MS; Khan M; Inayat A; Safi D
J Oncol Pharm Pract; 2024 Apr; 30(3):535-546. PubMed ID: 38454813
[TBL] [Abstract][Full Text] [Related]
3. Phase 1 study of selinexor plus carfilzomib and dexamethasone for the treatment of relapsed/refractory multiple myeloma.
Jakubowiak AJ; Jasielec JK; Rosenbaum CA; Cole CE; Chari A; Mikhael J; Nam J; McIver A; Severson E; Stephens LA; Tinari K; Rosebeck S; Zimmerman TM; Hycner T; Turowski A; Karrison T; Zonder JA
Br J Haematol; 2019 Aug; 186(4):549-560. PubMed ID: 31124580
[TBL] [Abstract][Full Text] [Related]
4. Selinexor in multiple myeloma.
Martino EA; Vigna E; Bruzzese A; Labanca C; Mendicino F; Lucia E; Olivito V; Zimbo A; Torricelli F; Neri A; Morabito F; Gentile M
Expert Opin Pharmacother; 2024 Mar; 25(4):421-434. PubMed ID: 38503547
[TBL] [Abstract][Full Text] [Related]
5. E3 ubiquitin ligase ASB8 promotes selinexor-induced proteasomal degradation of XPO1.
Kwanten B; Deconick T; Walker C; Wang F; Landesman Y; Daelemans D
Biomed Pharmacother; 2023 Apr; 160():114305. PubMed ID: 36731340
[TBL] [Abstract][Full Text] [Related]
6. Quality of life analyses in patients with multiple myeloma: results from the Selinexor (KPT-330) Treatment of Refractory Myeloma (STORM) phase 2b study.
Tremblay G; Daniele P; Breeze J; Li L; Shah J; Shacham S; Kauffman M; Engelhardt M; Chari A; Nooka A; Vogl D; Gavriatopoulou M; Dimopoulos MA; Richardson P; Biran N; Siegel D; Vlummens P; Doyen C; Facon T; Mohty M; Meuleman N; Levy M; Costa L; Hoffman JE; Delforge M; Kaminetzky D; Weisel K; Raab M; Dingli D; Tuchman S; Laurent F; Vij R; Schiller G; Moreau P; Richter J; Schreder M; Podar K; Parker T; Cornell RF; Lionel K; Choquet S; Sundar J
BMC Cancer; 2021 Sep; 21(1):993. PubMed ID: 34488662
[TBL] [Abstract][Full Text] [Related]
7. XPO1 blockade with KPT-330 promotes apoptosis in cutaneous T-cell lymphoma by activating the p53-p21 and p27 pathways.
Chakravarti N; Boles A; Burzinski R; Sindaco P; Isabelle C; McConnell K; Mishra A; Porcu P
Sci Rep; 2024 Apr; 14(1):9305. PubMed ID: 38653804
[TBL] [Abstract][Full Text] [Related]
8. The efficacy of selinexor (KPT-330), an XPO1 inhibitor, on non-hematologic cancers: a comprehensive review.
Landes JR; Moore SA; Bartley BR; Doan HQ; Rady PL; Tyring SK
J Cancer Res Clin Oncol; 2023 May; 149(5):2139-2155. PubMed ID: 35941226
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of CRM1-dependent nuclear export sensitizes malignant cells to cytotoxic and targeted agents.
Turner JG; Dawson J; Cubitt CL; Baz R; Sullivan DM
Semin Cancer Biol; 2014 Aug; 27():62-73. PubMed ID: 24631834
[TBL] [Abstract][Full Text] [Related]
10. Selinexor demonstrates anti-tumor efficacy in paired patient-derived xenograft models and hydrogel-embedded histoculture drug sensitivity test of penile cancer.
He Y; Mei J; Hao H; Liu F; Yi Y; Hu C; Zou F; Lu X
J Cancer Res Clin Oncol; 2023 Aug; 149(10):6931-6941. PubMed ID: 36840755
[TBL] [Abstract][Full Text] [Related]
11. RNA-binding protein hnRNPU regulates multiple myeloma resistance to selinexor.
Wang X; Xu J; Li Q; Zhang Y; Lin Z; Zhai X; Wang F; Huang J; Gao Q; Wen J; Li L; Feng Y; Luo H; Li Q; Liu X; Li J; Zhao F; Zhang L; Niu T; Sun C; Zheng Y
Cancer Lett; 2024 Jan; 580():216486. PubMed ID: 37984724
[TBL] [Abstract][Full Text] [Related]
12. Treatment of multiple myeloma with selinexor: a review.
Huang Q; Zhao R; Xu L; Hao X; Tao S
Ther Adv Hematol; 2024; 15():20406207231219442. PubMed ID: 38186637
[TBL] [Abstract][Full Text] [Related]
13. Inhibitor of the Nuclear Transport Protein XPO1 Enhances the Anticancer Efficacy of KRAS G12C Inhibitors in Preclinical Models of KRAS G12C-Mutant Cancers.
Khan HY; Nagasaka M; Li Y; Aboukameel A; Uddin MH; Sexton R; Bannoura S; Mzannar Y; Al-Hallak MN; Kim S; Beydoun R; Landesman Y; Mamdani H; Uprety D; Philip PA; Mohammad RM; Shields AF; Azmi AS
Cancer Res Commun; 2022 May; 2(5):342-352. PubMed ID: 35573474
[TBL] [Abstract][Full Text] [Related]
14. Optimal timing and drug combination of selinexor in multiple myeloma: a systematic review and meta-analysis.
Gu X; Sun C; Xu J; Lin Z; Zhang L; Zheng Y
Hematology; 2023 Dec; 28(1):2187972. PubMed ID: 36920065
[TBL] [Abstract][Full Text] [Related]
15. Protein biomarkers for response to XPO1 inhibition in haematologic malignancies.
Totiger TM; Chaudhry S; Musi E; Afaghani J; Montoya S; Owusu-Ansah F; Lee S; Schwartz G; Klimek V; Taylor J
J Cell Mol Med; 2023 Feb; 27(4):587-590. PubMed ID: 36722323
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of XPO1 with KPT-330 induces autophagy-dependent apoptosis in gallbladder cancer by activating the p53/mTOR pathway.
Zhao C; Yang ZY; Zhang J; Li O; Liu SL; Cai C; Shu YJ; Pan LJ; Gong W; Dong P
J Transl Med; 2022 Sep; 20(1):434. PubMed ID: 36180918
[TBL] [Abstract][Full Text] [Related]
17. Prognostic value and therapeutic targeting of XPO1 in chronic lymphocytic leukemia.
Xu Z; Pan B; Miao Y; Li Y; Qin S; Liang J; Kong Y; Zhang X; Tang J; Xia Y; Zhu H; Wang L; Li J; Wu J; Xu W
Clin Exp Med; 2023 Oct; 23(6):2651-2662. PubMed ID: 36738306
[TBL] [Abstract][Full Text] [Related]
18. Dual targeting of protein translation and nuclear protein export results in enhanced antimyeloma effects.
Li S; Fu J; Walker CJ; Yang J; Bhutani D; Chakraborty R; Mamillapalli N; Mapara MY; Landesman Y; Lentzsch S
Blood Adv; 2023 Jun; 7(12):2926-2937. PubMed ID: 36827679
[TBL] [Abstract][Full Text] [Related]
19. Impacting T-cell fitness in multiple myeloma: potential roles for selinexor and XPO1 inhibitors.
Binder AF; Walker CJ; Mark TM; Baljevic M
Front Immunol; 2023; 14():1275329. PubMed ID: 37954586
[TBL] [Abstract][Full Text] [Related]
20. XPO1 Enables Adaptive Regulation of mRNA Export Required for Genotoxic Stress Tolerance in Cancer Cells.
Marullo R; Rutherford SC; Revuelta MV; Zamponi N; Culjkovic-Kraljacic B; Kotlov N; Di Siervi N; Lara-Garcia J; Allan JN; Ruan J; Furman RR; Chen Z; Shore TB; Phillips AA; Mayer S; Hsu J; van Besien K; Leonard JP; Borden KLB; Inghirami G; Martin P; Cerchietti L
Cancer Res; 2024 Jan; 84(1):101-117. PubMed ID: 37801604
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]